非霍奇金淋巴瘤CAR T细胞治疗的物流挑战：医疗专业人员调查

数据集获取（Figshare）

• 源站标题：Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals
• DOI：10.6084/m9.figshare.27015014.v1
• 发布日期：2024-09-13
• 文件数：3 个
• 文件总体积：632.83 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Logistical_challenges_of_CAR_T-cell_therapy_in_non-Hodgkin_lymphoma_a_survey_of_healthcare_professionals/27015014

命令行下载

curl -L -o "ifon_a_2393566_sm0001.pdf" "https://ndownloader.figshare.com/files/49175114"
curl -L -o "ifon_a_2393566_sm0002.pdf" "https://ndownloader.figshare.com/files/49175117"
curl -L -o "ifon_a_2393566_sm0003.docx" "https://ndownloader.figshare.com/files/49175120"

文件清单

• ifon_a_2393566_sm0001.pdf（498.12 KB）
• ifon_a_2393566_sm0002.pdf（92.77 KB）
• ifon_a_2393566_sm0003.docx（41.94 KB）

文件总体积 632.83 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Aim: Characterize the logistical challenges faced by healthcare professionals (HCPs), patients and caregivers during the chimeric antigen receptor T-cell (CAR T) treatment process for non-Hodgkin lymphoma patients.
Materials & methods: HCPs in the US and UK experienced with CAR T administration participated in interviews and completed a web-based survey.
Results: A total of 133 (80 US, 53 UK) HCPs participated. Two or more logistical challenges were identified by ≥60% of respondents across all stages of the CAR T process. Commonly reported challenges were lengthy waiting periods, administrative and payer-related barriers, limited healthcare capacity, caregiver support and (particularly in the US) patient out-of-pocket costs.
Conclusion: The CAR T treatment process presents numerous challenges, highlighting an unmet need for more convenient therapies.
Chimeric antigen receptor T-cell (CAR T) therapy is a new treatment for patients with non-Hodgkin lymphoma that have not responded to other types of treatment. CAR T therapy uses a person’‘s own immune cells (T cells), which are modified in a laboratory to attack cancer cells. While CAR T therapy has the potential to be effective, there are challenges associated with the treatment process. In this study, we surveyed 133 healthcare professionals (HCPs) in the United States and United Kingdom to understand their experiences with logistical challenges involved in navigating the CAR T process. More than 60% of participants identified two or more logistical challenges at every stage of the CAR T treatment process. The most commonly reported challenges included long waiting periods, limited room at hospitals, availability of caregivers to support patients and issues related to out-of-pocket costs, travel and lodging for patients who are treated at specialized centers. In the United States, challenges related to insurance coverage and out-of-pocket costs for patients were highlighted. More than half of HCPs reported that patients’’ cancer getting worse while waiting to receive CAR T was a reason why patients may not proceed to treatment. While operational improvements might address some challenges in the CAR T treatment

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.27015014.v1（source: https://tandf.figshare.com/articles/dataset/Logistical_challenges_of_CAR_T-cell_therapy_in_non-Hodgkin_lymphoma_a_survey_of_healthcare_professionals/27015014）。